Spots Global Cancer Trial Database for pet imaging
Every month we try and update this database with for pet imaging cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients | NCT01222728 | Neoplasms Nervous System ... Vestibular Dise... | 18 Years - 50 Years | National Institutes of Health Clinical Center (CC) | ||
| A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors | NCT01176500 | Colon Cancer Lung Cancer Cervical Cancer Renal Cell Carc... Uterine Cancer | (18)Fluciclatid... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| PET Imaging in Potentially Surgically Resectable Non-small Cell Lung Cancers | NCT00136890 | Non-small-cell ... | PET Imaging | 18 Years - | Ontario Clinical Oncology Group (OCOG) | |
| Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer | NCT02260817 | Metastatic Pros... | 11C-choline Inj... | 18 Years - | Global Isotopes, LLC d/b/a Zevacor Molecular | |
| Pembrolizumab-PET Imaging | NCT02760225 | Melanoma Non-small Cell ... | 89Zr-Pembrolizu... 89Zr-Pembrolizu... | 18 Years - | University Medical Center Groningen | |
| [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer | NCT00588185 | Prostate Cancer | [18F]-Fluoro-2-... | - | Memorial Sloan Kettering Cancer Center | |
| 18F ML-10 for Early Detection of Response of Brain Metastases to SRS | NCT00696943 | Metastasis to B... | ([18F]-ML-10) | 18 Years - | Aposense Ltd. | |
| Bioactive Glass Granules in Filling of Bone Defects | NCT01304121 | Bone Tumors | Bioactive glass... | 18 Years - | Turku University Hospital | |
| Imaging HSP90 Inhibitor AUY922 on VEGF-89ZR-bevacizumab Positron Emission Tomography (PET) | NCT01081613 | Breast Cancer | 89Zr-bevacizuma... | 18 Years - | University Medical Center Groningen | |
| FAZA PET/MRI Sarcoma | NCT03418818 | Sarcoma | 18F-FAZA Pimonidazole | 18 Years - | University Health Network, Toronto | |
| Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer | NCT03822845 | Prostatic Neopl... Prostatic Neopl... | Ga-68 PSMA-HBED... | 18 Years - | University of Iowa | |
| Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients | NCT03535545 | Pulmonary Fibro... Lung Cancer | [68Ga]CBP8 PET Imaging | 18 Years - 80 Years | Massachusetts General Hospital | |
| A Study of [F-18]HX4 (PET Imaging)Evaluated in Head and Neck Cancer Patients | NCT01506427 | Head and Neck C... | [F-18] HX4 | - | Siemens Molecular Imaging | |
| 68Ga-DOTA-TATE PET/CT Imaging in NETs | NCT04847505 | Neuroendocrine ... | 68Ga-DOTA-TATE | - | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | |
| (PET) Imaging in the Management of Patients With Solitary Pulmonary Nodules | NCT00032331 | Benign and Mali... | PET Imaging CT scan | - | VA Office of Research and Development | |
| Molecular Imaging of Pituitary Adenomas | NCT03815838 | Pituitary Adeno... | PET imaging | 16 Years - | Cardiff University | |
| PET Imaging in Potentially Surgically Resectable Non-small Cell Lung Cancers | NCT00136890 | Non-small-cell ... | PET Imaging | 18 Years - | Ontario Clinical Oncology Group (OCOG) | |
| 68Ga-PSMA-617 PET/CT for PSMA-expressing Tumor: a Pragmatic Study | NCT05228106 | Solid Cancers | [68Ga]-PSMA-617 | - | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | |
| 89Zr-trastuzumab PET for Imaging the Effect of HSP90 Inhibition | NCT01081600 | Breast Cancer | Imaging with 89... | 18 Years - | University Medical Center Groningen | |
| Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy. | NCT00805636 | Brain Metastase... Solid Tumors | 2-(5-fluoro-pen... Stereotactic Ra... Positron Emissi... | 18 Years - | Aposense Ltd. | |
| Molecular Imaging of Pituitary Adenomas | NCT03815838 | Pituitary Adeno... | PET imaging | 16 Years - | Cardiff University | |
| PD-L1 PET Imaging in Melanoma Patients | NCT03520634 | Melanoma | PD-L1 PET imagi... | 18 Years - | University Medical Center Groningen | |
| Imaging HSP90 Inhibitor AUY922 on VEGF-89ZR-bevacizumab Positron Emission Tomography (PET) | NCT01081613 | Breast Cancer | 89Zr-bevacizuma... | 18 Years - | University Medical Center Groningen | |
| Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization | NCT02471313 | Liver Cancer Liver Neoplasm Hepatocellular ... HCC | [18F] FMISO | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Safety and Imaging Study of GC1008 in Glioma | NCT01472731 | Primary Brain T... | 89Zr-GC1008 GC1008 | 18 Years - 75 Years | University Medical Center Groningen | |
| Effects of Hormone Stimulation on Brain Scans for Cushing s Disease | NCT01459237 | Pituitary Neopl... | Acthrel | 8 Years - | National Institutes of Health Clinical Center (CC) | |
| Pembrolizumab-PET Imaging | NCT02760225 | Melanoma Non-small Cell ... | 89Zr-Pembrolizu... 89Zr-Pembrolizu... | 18 Years - | University Medical Center Groningen | |
| PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study | NCT02307630 | Melanoma Neuroblastoma Sarcoma | 124I-Humanized ... | 3 Years - 90 Years | Memorial Sloan Kettering Cancer Center | |
| 18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery | NCT06048094 | Brain Metastase... Brain Metastase... Brain Cancer | 18F fluciclovin... | 18 Years - | Baptist Health South Florida | |
| Study of PET Imaging With 18F-TFB in Patients With Thyroid Cancer | NCT03196518 | Thyroid Cancer | PET Imaging 18F-tetrafluoro... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Para-Aortic Lymph Nodal Staging & Evaluation of Treatment Outcome by 18F FDG-PET in Advanced Cancer Cervix | NCT00193752 | Cancer of Cervi... | PET IMAGING | 18 Years - 65 Years | Tata Memorial Hospital | |
| FAZA PET/MRI Pancreas | NCT04395469 | Pancreatic Aden... Locally Advance... Unresectable Pa... | 18F-FAZA | 18 Years - | University Health Network, Toronto | |
| CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas | NCT03387592 | Neuroendocrine ... | CPT-11 Calcio levofoli... 5-Fluorouracil Capecitabine Temozolomide | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging | NCT02462239 | Muscle-invasive... | Whole-body FDG ... | 18 Years - | Ontario Clinical Oncology Group (OCOG) | |
| Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients | NCT00708448 | Cancer Non Small Cell ... | PET Imaging Erlotinib Bevacizumab | 18 Years - | University of Utah | |
| 68Ga-PSMA-617 PET/CT for PSMA-expressing Tumor: a Pragmatic Study | NCT05228106 | Solid Cancers | [68Ga]-PSMA-617 | - | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | |
| Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization | NCT02471313 | Liver Cancer Liver Neoplasm Hepatocellular ... HCC | [18F] FMISO | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| FAZA PET/MRI Pancreas | NCT04395469 | Pancreatic Aden... Locally Advance... Unresectable Pa... | 18F-FAZA | 18 Years - | University Health Network, Toronto | |
| 89Zr-RO5323441 PET Imaging in Glioblastoma | NCT01622764 | Glioblastoma | Molecular imagi... | 18 Years - | University Medical Center Groningen | |
| Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy. | NCT00805636 | Brain Metastase... Solid Tumors | 2-(5-fluoro-pen... Stereotactic Ra... Positron Emissi... | 18 Years - | Aposense Ltd. | |
| 18F ML-10 for Early Detection of Response of Brain Metastases to SRS | NCT00696943 | Metastasis to B... | ([18F]-ML-10) | 18 Years - | Aposense Ltd. | |
| Study of PET Imaging With 18F-TFB in Patients With Thyroid Cancer | NCT03196518 | Thyroid Cancer | PET Imaging 18F-tetrafluoro... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R) | NCT01697930 | Solid Malignanc... Lymphoma | [18F] 4-L-Fluor... | 21 Years - 90 Years | Memorial Sloan Kettering Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
